RecruitingNCT06745830

Lymph Node Pathologic Grading Strategy

Lymph Node Pathologic Grading Strategy: Under the Backdrop of the IASLC Grading System for Invasive Lung Adenocarcinoma - a Retrospective Cohort Study

Sponsor

Fudan University

Enrollment

2,998 participants

Start Date

Apr 10, 2024

Study Type

OBSERVATIONAL

Conditions

Lung Adenocarcinoma

Summary

The percentage of high-grade patterns in metastatic LNs (mLNs) that can predict poor outcomes has yet to be determined. Additionally, the potential implications of other histologic patterns in metastatic lymph nodes on patient outcomes warrant further investigation. We conducted a retrospective cohort study to investigate the prognostic value of pathologic pattern in metastatic lymph nodes.

Eligibility

Plain Language Summary

Simplified for easier understanding

This is a retrospective study (looking at past patient data) that develops and tests a new way to classify lymph node involvement in people who had surgery for invasive lung adenocarcinoma (a type of lung cancer) at a single cancer center in China. It aims to better predict patient outcomes based on lymph node pathology. **You may be eligible if...** - You had surgery to remove invasive lung adenocarcinoma at Fudan University Shanghai Cancer Center between January 2011 and September 2021 **You may NOT be eligible if...** - Your tumor was an early or special variant (adenocarcinoma in situ, minimally invasive, mucinous) - Your genetic mutation data is incomplete - Your pathology slides are not available for review Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.